Is AbbVie Inc. (ABBV) Overvalued?
We dive into why AbbVie Inc. (ABBV) could be considered overvalued on 2026-07-14, based on AAII’s Value Score and Grade.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Commentary & Analysis
Is AbbVie Inc. (ABBV) Overvalued?
We dive into why AbbVie Inc. (ABBV) could be considered overvalued on 2026-07-13, based on AAII’s Value Score and Grade.Tudor Pop
Is AbbVie Inc. (ABBV) Overvalued?
We dive into why AbbVie Inc. (ABBV) could be considered overvalued on 2026-07-10, based on AAII’s Value Score and Grade.Tudor Pop
Is AbbVie Inc. (ABBV) Overvalued?
We dive into why AbbVie Inc. (ABBV) could be considered overvalued on 2026-07-09, based on AAII’s Value Score and Grade.Tudor Pop
Is AbbVie Inc. (ABBV) Overvalued?
We dive into why AbbVie Inc. (ABBV) could be considered overvalued on 2026-07-08, based on AAII’s Value Score and Grade.Jenna Brashear
Financial Summary
| Share Statistics | ABBV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $454,790.1 | $251.9 | 100% |
|
| Shares Out (Mil) | 1,774.0 | 50.8 | 97% |
|
| Institutional Ownership | 99.9% | 92.0% | 96% |
|
| Float (Mil) | 1,763.6 | 40.5 | 95% |
|
| Beta | 0.30 | 0.95 | 17% |
|
| Avg Daily Volume (000s) | 5,412 | 447 | 93% |
|
| Price Change (52-week) |
34.6% | 54.2% | 72% |
|
| Growth | ABBV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.0% | 14.0% | 41% |
|
| Net Income (5yr) | (1.7%) | (9.8%) | 37% |
|
| EPS (5yr) | (2.8%) | 16.3% | 27 |
|
| Dividends (5yr) | 6.6% | 0.0% | 99% |
|
| Cash Flow (5yr) | 61.0% | (15.6%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 22 | 26 | 24 | |
| Current EPS | $3.608 | $14.123 | $16.296 | |
| Month Ago EPS | $3.768 | $14.247 | $16.263 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 2 | |
| Three Months Ago EPS | $3.761 | $14.271 | $16.155 | |
| Year/Year Chg | 832.3% | 498.4% | 661.5% | |
| Financials | ABBV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $62,819 | $39 | 98% |
|
| Net Income (TTM) (Mil) | $3,635 | ($43) | 96% |
|
| EPS (TTM) | $2.032 | ($1.600) | 72% |
|
| Operating Cash Flow (TTM) (Mil) | $21,224 | ($30) | 99% |
|
| Net Cash Flow (TTM) (Mil) | $4,216 | $3 | 99% |
|
| Long-Term Debt (Q1) (Mil) | $64,572 | $5 | 99% |
|
| Enterprise Value (Q1) (Mil) | $435,952 | $182 | 99% |
|
| Valuation | ABBV | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.60 | na |
|
| P/E | 126.8 | 18.6 | 95% |
|
| Dividend Yield | 2.7% | 0.0% | 82% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ABBV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 72.0% | 63.8% | 83% |
|
| Net Margin | 5.8% | (64.7%) | 51% |
|
| ROA | 2.7% | (49.7%) | 60% |
|
| ROE | (138.8%) | (55.4%) | 7% |
|
| Liabilities to Assets | 104.8% | 30.3% | 95% |
|
| F-Score | 6 | 3 | 69% |
|
AbbVie Inc. did not pass any screens on 7/30/2026.
